TAC-GPC3

N/A

Report date: 2022/12/15 16:16:23

Base Information

Drug NameTAC-GPC3
Drug Alias NameTAC-GPC3
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionGlypican-3 inhibitorsT lymphocytes stimulantsImmunostimulants
TargetsGlypican-3
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTriumvira Immunologics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTriumvira Immunologics Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A